2-[5-(Adamantan-1-yloxymethyl)-2-cyclohexyl-1H-imidazole-4-yl]-benzooxazole-5-carboxylic acid methyl ester | 372956-87-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 2-[5-(Adamantan-1-yloxymethyl)-2-cyclohexyl-1H-imidazole-4-yl]-benzooxazole-5-carboxylic acid methyl ester
• 英文别名: methyl 2-[5-(1-adamantyloxymethyl)-2-cyclohexyl-1H-imidazol-4-yl]-1,3-benzoxazole-5-carboxylate
• CAS: 372956-87-1
• 化学式: C₂₉H₃₅N₃O₄
• 分子量: 489.615
• InChiKey: YYLPVVBEKVQTNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  90.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-[5-(Adamantan-1-yloxymethyl)-2-cyclohexyl-1H-imidazole-4-yl]-benzooxazole-5-carboxylic acid methyl ester 在 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 水 为溶剂， 以74%的产率得到2-[5-(Adamantan-1-yloxymethyl)-2-cyclohexyl-1H-imidazole-4-yl]-benzooxazole-5-carboxylic acid
  参考文献：
  名称：

  Gastrin and cholecystokinin receptor ligands (III)

  摘要：

  公式（I）的化合物及其药学上可接受的盐是胃泌素和/或胆囊收缩素受体的配体。X和Y分别独立为═N—、—N(R5)—（R5选自H、Me、Et、Pr、Bn、OH和—CH2COOR6，其中R6代表H、Me、Et、Pr或Bn）、═CH—、—O—或—S—；n为1至4；A是一个可选择替代的5-或6-成员碳环，其中（a）1或2个C原子可选择替换为N、O和/或S原子，（b）A与公式（I）中的芳香基融合形成一个融合的双环，并且（c）含有X和Y的环与A的一个C原子连接；R1为H或C1至C15烃基，其中最多可有三个C原子可选择替换为N、O和/或S原子，最多可有三个H原子可选择替换为卤素原子；R2选自H、Me、Et、Pr和OH，当n大于1时，每个R2独立选择自H、Me、Et、Pr和OH；R3（当n为1时）选自H、Me、Et和Pr；或（当n大于1时）每个R3独立选择自H、Me、Et和Pr，或相邻碳原子上的两个R3基团连接形成一个C3到C6的碳环，或相邻碳原子上缺少两个R3基团，这两个基团由双键连接；或同一碳原子上的R2和R3共同表示一个═O基团；R4为C1至C15烃基，其中最多可有两个C原子可选择替换为N、O和/或S原子，最多可有三个H原子可选择替换为卤素原子；V为—CO—NH—SO2—Ph、—SO2—NH—CO—Ph、—CH2OH或式—R7U的基团（其中U为—COOH、四唑基、—CONHOH或—SO3H；而R7为键；C1至C6烃基亚烷，可选择地被羟基、氨基或乙酰胺基替代；—O—（C1至C3烷基）—；—SO2NR8—CHR9—；—CO—NR8—CHR9—，R8和R9独立选择自H和甲基；或—NH—（CO）c—CH2，c为0或1）；或其药学上可接受的盐。还描述了包含公式（I）化合物的组合物。

  公开号：

  US20030191116A1

文献信息

• US7034048B2
  申请人：——

  公开号：US7034048B2

  公开（公告）日：2006-04-25
• [EN] GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (III)<br/>[FR] LIGANDS (III) DES RECEPTEURS DE LA CHOLECYSTOKININE ET DE LA GASTRINE
  申请人：BLACK JAMES FOUNDATION

  公开号：WO2001085724A1

  公开（公告）日：2001-11-15

  Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently =N-, -N(R5)-(R5 being selected from H, Me, Et, Pr, Bn, OH and -CH¿2COOR?6, wherein R6 represents H, Me, Et, Pr or Bn), =CH-, -O- or -S-; n is from 1 to 4; A is an optionally substituted 5- or 6- membered carbocyclic ring wherein (a) 1 or 2 C atoms may optionally be replaced by N, O and/or S atoms, (b) A is fused with the aromatic group in formula (I) to form a fused bicycle, and (c) the ring containing X and Y is linked to a C atom of A; R1 is H or C¿1? to C15 hydrocarbyl wherein up to three C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; R?2¿ is selected from H, Me, Et, Pr and OH, each R2 being independently selected from H, Me, Et, Pr and OH when n is greater than 1; R3 (when n is 1) is selected from H, Me, Et and Pr; or (when n is greater than 1) each R3 is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbn atoms are linked to form a C¿3? to C6 carbocylic ring, or two R?3¿ groups are absent from neighbouring carbon atoms which are linked by a double bond; or R?2 and R3¿ on the same carbon atom together represent an =O group; R4 is C1 to C15 hydrocarbyl wherein up to two C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; V is -CO-NH-SO2-Ph, -SO2-NH-CO-Ph, -CH2OH, or a group of the formula -R7U, (wherein U is -COOH, tetrazolyl, -CONHOH or -SO¿3?H; and R?7¿ is a bond; C¿1? to C6 hydrocarbylene, optionally substituted by hydroxy, amino or acetamido; -O-(C1 to C3 alkylene)-; -SO2NR?8-CHR9¿-; -CO-NR?8-CHR9-, R8 and R9¿ being independently selected from H and methyl; or -NH-(CO)¿c?-CH2, c being 0 or 1); or a pharmaceutically acceptable salt thereof. Compositions comprising a compound a formula (I) are also described.